Skip to content

Functional Immuno-monitoring of Cystic Fibrosis Patients

Functional Immuno-monitoring of Cystic Fibrosis Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00023486
Enrollment
25
Registered
2020-11-23
Start date
2020-10-28
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E84

Interventions

Group 1: 2 timepoints: before therapy start with CFTR modulator and after 6 months examinations: spirometry, sweat test, functional immunomonitoring

Sponsors

Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age at least 18 years; indication for Kaftrio therapy; homozygous deltaF508 mutation or compound heterozygous for deltaF508 and a minimal function mutation

Exclusion criteria

Exclusion criteria: acute infection, fever or surgical intervention within the last 7 days; blood transfusion within the last 3 months; immunosuppressive therapy; systemic antibiotic therapy within the last 3 days

Design outcomes

Primary

MeasureTime frame
experimental parameters of neutrophil function timepoints: before start of CFTR modulator therapy and 6 months afterwards methods: flow cytometry

Secondary

MeasureTime frame
lung function parameters timepoints: before start of CFTR modulator therapy and 6 months afterwards methods: spirometry

Countries

Germany

Contacts

Public ContactHanna Schmidt

Department of Pediatric and Adolescent Medicine, University Hospital Ulm

hanna.schmidt@uni-ulm.de0731/50057194

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026